# US 2026/0097019 A1 · Methods of use for trisubstituted benzotriazole derivatives as dihydroorotate oxygenase inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0097019 A1
- Document ID: US20260097019A1
- Status: Published application
- Kind: A1
- Application number: 19/195,209
- Filed: 2025-04-30
- Published: 2026-04-09
- Earliest claimed: 2017-04-24
- Assignees: Aurigene Oncology Limited
- Applicants: Aurigene Oncology Limited
- Inventors: Kavitha Nellore; Subramanya Hosahalli
- Web page: https://patentgrep.com/patent/US20260097019A1

## CPC

- A61K 31/4192: 1,2,3-Triazoles
- A61K 31/454: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A61K 31/496: Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61P 35/02: specific for leukemia
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides methods for treating a cancer in a subject and for inhibiting tumor growth, metastasis or a dihydrorotate oxygenase enzyme activity of a tumor or cancer cell. At least one trisubstituted benzotriazole derivative with the formula (I) is administered to the subject or is contacted with the cancer cell. Compounds of formula (I) have substituents R1, R2 and R3 which have the meanings given in the specification, and pharmaceutically acceptable salts thereof.

## Claims

### Claim 1

A method of treating a cancer selected from acute myeloid leukemia, multiple myeloma, B-prolymphocytic leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, Hodgkin's disease, non-Hodgkin's lymphoma, follicular lymphoma, diffuse large B cell lymphoma, anaplastic large cell lymphoma, mantle cell lymphoma, lung cancer, breast cancer, triple negative breast cancer, melanoma, glioblastoma, prostate cancer, colon cancer, pancreatic cancer, bone cancer, cancer of the head or neck, skin cancer, cutaneous or intraocular malignant endometrium, carcinoma of the cervix, carcinoma of the vagina, carcinoma of the vulva, cancer of the esophagus, cancer of the small intestine, cancer of the endocrine system, cancer of the thyroid gland, cancer of the parathyroid gland, cancer of the adrenal gland, sarcoma of soft tissue, cancer of the urethra, cancer of the penis, solid tumors of childhood, lymphocytic lymphoma cancer of the bladder, cancer of the kidney or ureter, carcinoma of the renal pelvis, neoplasm of the central nervous system (CNS), primary CNS lymphoma, tumor angiogenesis, spinal axis tumor, brain stem glioma, pituitary adenoma, Kaposi's sarcoma, epidermoid cancer, squamous cell cancer, T-cell lymphoma, environmentally induced cancer, and a PTEN mutant cancer in a subject, comprising administering to the subject a therapeutically effective amount of a compound represented by the following structural formula:
or a pharmaceutically acceptable salt thereof; wherein:
the dotted lines [] in the ring represent an optional bond which is be present in any stable combination;
R1 is selected from hydrogen and alkyl;
R2 is -A-R4;
A is arylene or tetrasubstituted arylene; wherein the substituent is halogen;
R3 is selected from hydroxy and amino;
R4 is selected from an aryl and a heteroaryl that is optionally substituted with one or more R5;
R5 is selected from alkyl and —(CH2)nN(Ra)Rb;
Ra and Rb are independently selected from hydrogen, alkyl and —C(O)alkyl;
alternatively Ra and Rb can be taken together with the nitrogen atom to which they are attached to form a 4-6 membered heterocyclyl containing 0-2 additional heteroatoms independently selected from O and N and is optionally substituted with alkyl; and
n is an integer selected from 0 and 1.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the cancer is selected from acute myeloid leukemia, multiple myeloma, B-prolymphocytic leukemia, non-Hodgkin's lymphoma, diffuse large B cell lymphoma, anaplastic large cell lymphoma, mantle cell lymphoma, triple negative breast cancer, melanoma, prostate cancer, and cancer of the esophagus.

### Claim 3 (depends on 1, 2)

The method according to any one of claims 1 and 2, wherein the cancer is acute myeloid leukemia.

### Claim 4 (depends on 1, 2)

The method according to any one of claims 1 and 2, wherein the cancer is multiple myeloma.

### Claim 5 (depends on 1, 2)

The method according to any one of claims 1 and 2, wherein the cancer is B-prolymphocytic leukemia.

### Claim 6 (depends on 1, 2)

The method according to any one of claims 1 and 2, wherein the cancer is non-Hodgkin's lymphoma.

### Claim 7 (depends on 1, 2)

The method according to any one of claims 1 and 2, wherein the cancer is diffuse large B cell lymphoma.

### Claim 8 (depends on 1, 2)

The method according to any one of claims 1 and 2, wherein the cancer is anaplastic large cell lymphoma.

### Claim 9 (depends on 1, 2)

The method according to any one of claims 1 and 2, wherein the cancer is mantle cell lymphoma.

### Claim 10 (depends on 1, 2)

The method according to any one of claims 1 and 2, wherein the cancer is triple negative breast cancer.

### Claim 11 (depends on 1, 2)

The method according to any one of claims 1 and 2, wherein the cancer is melanoma.

### Claim 12 (depends on 1, 2)

The method according to any one of claims 1 and 2, wherein the cancer is prostate cancer.

### Claim 13 (depends on 1, 2)

The method according to any one of claims 1 and 2, wherein the cancer is cancer of the esophagus.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

The method according to any one of claims 1-13, wherein the compound is selected from:
or a pharmaceutically acceptable salt thereof.

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

The method according to any one of claims 1-14, wherein the compound is
or a pharmaceutically acceptable salt thereof.

### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

The method according to any one of claims 1-14, wherein the compound is
or a pharmaceutically acceptable salt thereof.

### Claim 17 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

The method according to any one of claims 1-14, wherein the compound is
or a pharmaceutically acceptable salt thereof.

### Claim 18 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

The method according to any one of claims 1-14, wherein the compound is
or a pharmaceutically acceptable salt thereof.

### Claim 19 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

The method according to any one of claims 1-14, wherein the compound is
or a pharmaceutically acceptable salt thereof.

### Claim 20 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

The method according to any one of claims 1-14, wherein the compound is
or a pharmaceutically acceptable salt thereof.
